Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In asymptomatic patients with inflammatory bowel disease (IBD), "monitoring" involves repeated testing aimed at early recognition of disease exacerbation. We aimed to determine the usefulness of repeated fecal calprotectin (FC) measurements to predict IBD relapses by a systematic literature review. METHODS: An electronic search was performed in Medline, Embase, and Cochrane from inception to April 2016. Inclusion criteria were prospective studies that followed patients with IBD in remission at baseline and had at least 2 consecutive FC measurements with a test interval of 2 weeks to 6 months. Methodological assessment was based on the second Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) checklist. RESULTS: A total of 1719 articles were identified; 193 were retrieved for full text review. Six studies met eligibility for inclusion. The time interval between FC tests varied between 1 and 3 months. Asymptomatic patients with IBD who had repeated FC measurements above the study's cutoff level had a 53% to 83% probability of developing disease relapse within the next 2 to 3 months. Patients with repeated normal FC values had a 67% to 94% probability to remain in remission in the next 2 to 3 months. The ideal FC cutoff for monitoring could not be identified because of the limited number studies meeting inclusion criteria and heterogeneity between selected studies. CONCLUSIONS: Two consecutively elevated FC values are highly associated with disease relapse, indicating a consideration to proactively optimize IBD therapy plans. More prospective data are necessary to assess whether FC monitoring improves health outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Halpin, S. J., & Ford, A. C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.260 · Cited by 607 · cited 1×
“This rationale is particularly true in children affected by IBD and patients with concomitant irritable bowel syndrome.(8,9) Calprotectin is a protein released by activated or damaged granulocytes, monocytes, macrophages and epithelial cells.”
BackgroundBerni Canani, R., Terrin, G., Rapacciuolo, L., Miele, E., Siani, M. C., Puzone, C., Cosenza, L., Staiano, A., & Troncone, R. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2008.01.017 · Cited by 175
Cited by
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.031 · Cited by 2,911
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Self-citationColombel, J.-F., Panaccione, R., Bossuyt, P., Lukas, M., Baert, F., Vaňásek, T., Danalioglu, A., Novacek, G., Armuzzi, A., Hébuterne, X., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32641-7 · Cited by 921
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
van Rheenen, P. F., Aloi, M., Assa, A., Bronsky, J., Escher, J. C., Fagerberg, U. L., Gasparetto, M., Gerasimidis, K., Griffiths, A., Henderson, P., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa161 · Cited by 729
Self-citationPositioning and usefulness of biomarkers in inflammatory bowel disease
Sakurai, T., & Saruta, M. (2023) · Digestion · doi:10.1159/000527846 · Cited by 156
Metadata
- Authors
- Heida, A., Park, K. T., & van Rheenen, P. F.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06
- Volume
- 23
- Issue
- 6
- Pages
- 894-902
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2604490502
- Cited by
- 150
- References
- 3
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. https://app.cochat.ai/papers/10.1097/mib.0000000000001082
- The paper
- Heida, A., Park, K. T., & van Rheenen, P. F. (2017). Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000001082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.